SCHEMBL25035365

SCHEMBL25035365

Cc1ccc(CS(=O)(=O)Nc2c(F)cc(-c3nc4cnc(N)nc4n(C(C)C)c3=O)cc2F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.47
MTOR P42345 4/20 0.37
RORC P51449 2/20 0.35
USP2 O75604 4/20 0.34
CASP1 P29466 4/20 0.34
HIF1A Q16665 4/20 0.34
CYP1A2 P05177 3/20 0.34
CASP7 P55210 3/20 0.34
TSHR P16473 1/20 0.34
BRAF P15056 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
RPS6KA3 P51812 1/20 0.33
F2 P00734 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 2/20 0.33
PIK3CA P42336 1/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035661 0.94 ERN1 (0.48) ERN1RORCUSP2CASP1HIF1A
SCHEMBL25034068 0.93 ERN1 (0.47) ERN1RORCUSP2CASP1HIF1A
SCHEMBL25034190 0.92 ERN1 (0.48) ERN1RORCUSP2CASP1HIF1A
SCHEMBL25034231 0.92 ERN1 (0.46) ERN1MTORRORCUSP2CASP1
SCHEMBL25034061 0.90 ERN1 (0.44) ERN1MTORUSP2CASP1HIF1A
SCHEMBL25035364 0.90 ERN1 (0.42) ERN1MTORRORCBRAFF2
SCHEMBL25035327 0.86 ERN1 (0.46) ERN1MTORBRAFRPS6KA3F2
SCHEMBL25034135 0.85 ERN1 (0.50) ERN1MTORRORCUSP2CASP1
SCHEMBL25035335 0.84 ERN1 (0.58) ERN1USP2CASP1HIF1ACYP1A2
SCHEMBL22200826 0.84 ERN1 (0.39) ERN1MTORRORCUSP2CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885MTOR 487/4885RORC 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.